Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D06QSN
|
|||
| Former ID |
DIB012991
|
|||
| Drug Name |
Itolizumab
|
|||
| Synonyms |
T-1h-mAb; T-1h-mAb); Anti-CD6 humanized monoclonal antibody, Center of Molecular Immunology/Biocon Biopharmaceuticals; Anti-CD6 humanized monoclonal antibody (rheumatoid arthritis/ psoriasis/ T-cell lymphoma), CIM/Biocon Biopharmaceuticals
Click to Show/Hide
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Type-1 diabetes [ICD-11: 5A10; ICD-9: 250] | Phase 3 | [1] | |
| Company |
Dermatology; The Center of Molecular Immunology
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | T-cell differentiation antigen CD6 (TP120) | Target Info | . | [1] |
| KEGG Pathway | Cell adhesion molecules (CAMs) | |||
| NetPath Pathway | IL2 Signaling Pathway | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Efficacy and safety of itolizumab, a novel anti-CD6 monoclonal antibody, in patients with moderate to severe chronic plaque psoriasis: results of a double-blind, randomized, placebo-controlled, phase-III study. J Am Acad Dermatol. 2014 Sep;71(3):484-92. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.